Hardman Johnston Global Advisors LLC Has $39.02 Million Stock Position in Boston Scientific Co. (NYSE:BSX)

Hardman Johnston Global Advisors LLC boosted its position in shares of Boston Scientific Co. (NYSE:BSXFree Report) by 3.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 674,940 shares of the medical equipment provider’s stock after purchasing an additional 24,810 shares during the period. Boston Scientific accounts for approximately 1.3% of Hardman Johnston Global Advisors LLC’s portfolio, making the stock its 27th biggest position. Hardman Johnston Global Advisors LLC’s holdings in Boston Scientific were worth $39,018,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. Highview Capital Management LLC DE acquired a new stake in Boston Scientific during the fourth quarter valued at $638,000. Helios Capital Management PTE. Ltd. acquired a new stake in Boston Scientific during the fourth quarter valued at $867,000. Wealthspan Partners LLC acquired a new stake in Boston Scientific during the fourth quarter valued at $213,000. Sapient Capital LLC acquired a new stake in Boston Scientific during the fourth quarter valued at $7,332,000. Finally, Cerity Partners LLC boosted its position in Boston Scientific by 35.8% during the fourth quarter. Cerity Partners LLC now owns 551,421 shares of the medical equipment provider’s stock valued at $31,877,000 after purchasing an additional 145,359 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig sold 7,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total value of $455,210.00. Following the sale, the director now directly owns 41,374 shares in the company, valued at approximately $2,690,551.22. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Edward J. Ludwig sold 7,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total value of $455,210.00. Following the sale, the director now directly owns 41,374 shares in the company, valued at approximately $2,690,551.22. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Daniel J. Brennan sold 13,662 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total value of $899,779.32. Following the completion of the sale, the chief financial officer now owns 271,542 shares in the company, valued at $17,883,756.12. The disclosure for this sale can be found here. Insiders have sold 50,979 shares of company stock worth $3,418,529 over the last three months. Company insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on BSX shares. Wells Fargo & Company boosted their price target on Boston Scientific from $70.00 to $72.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Royal Bank of Canada boosted their price target on Boston Scientific from $67.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Citigroup boosted their price target on Boston Scientific from $71.00 to $79.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. JPMorgan Chase & Co. boosted their price target on Boston Scientific from $60.00 to $72.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Finally, BTIG Research reaffirmed a “buy” rating and issued a $64.00 price target on shares of Boston Scientific in a research report on Friday, December 29th. Two equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $68.14.

Check Out Our Latest Report on Boston Scientific

Boston Scientific Stock Performance

BSX traded down $0.77 on Friday, hitting $68.07. 4,995,109 shares of the stock traded hands, compared to its average volume of 6,372,261. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $69.21. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $99.87 billion, a PE ratio of 64.34, a P/E/G ratio of 2.40 and a beta of 0.78. The business has a fifty day moving average price of $66.91 and a two-hundred day moving average price of $59.22.

Boston Scientific (NYSE:BSXGet Free Report) last issued its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.04. Boston Scientific had a return on equity of 15.99% and a net margin of 11.19%. The firm had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. During the same period in the previous year, the company posted $0.45 earnings per share. On average, research analysts predict that Boston Scientific Co. will post 2.25 EPS for the current fiscal year.

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Further Reading

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.